OnKure Insider Leverone Files Form 4 on Ownership Changes

TL;DR

**OnKure insider Leverone just filed a Form 4, signaling potential changes in his stock ownership.**

AI Summary

This Form 4 filing, dated March 24, 2026, reports that Jason A. Leverone, an insider at OnKure Therapeutics, Inc., has filed a statement of changes in beneficial ownership of securities. While the filing itself doesn't detail specific transactions, it indicates that Leverone, whose CIK is 0001692747, is a reporting person for OnKure Therapeutics, Inc. (CIK: 0001637715). This matters to investors because it signals that an insider's holdings may have changed, and future detailed transaction data within the filing would reveal if they are buying or selling, which can influence stock perception.

Why It Matters

This filing indicates potential changes in an insider's stake, which can be a signal of their confidence in the company's future prospects. Investors often watch insider activity for clues about a company's health.

Risk Assessment

Risk Level: low — This filing is purely administrative, indicating a change in beneficial ownership, and does not inherently pose a direct risk without transaction details.

Analyst Insight

An investor should monitor subsequent filings from Leverone Jason A. to identify specific transactions (buys or sells) and their sizes, as this initial Form 4 only signals a change in beneficial ownership without detailing the transaction itself.

Key Players & Entities

• Leverone Jason A. (person) — Reporting person for OnKure Therapeutics, Inc.
• OnKure Therapeutics, Inc. (company) — The issuer of the securities
• 2026-03-24 (date) — Filing Date
• 0001692747 (person) — CIK for Leverone Jason A.
• 0001637715 (company) — CIK for OnKure Therapeutics, Inc.

FAQ

Key Financial Figures

• $3.995 — multiple trades at prices ranging from $3.995 to $4.235. The price reported above ref
• $4.235 — trades at prices ranging from $3.995 to $4.235. The price reported above reflects the

Filing Documents

• form4-03242026_100303.html (4)
• form4-03242026_100303.xml (4) — 4KB
• 0001692747-26-000001.txt ( ) — 6KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Leverone Jason A. (Last) (First) (Middle) C/O ONKURE THEREAPEUTICS, INC. 6707 WINCHESTER CIRCLE, SUITE 400 (Street) BOULDER COLORADO 80301 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol OnKure Therapeutics, Inc. [ OKUR ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 03/23/2026 S (1) 301 D $ 4.1565 (2) 16,000 (3) D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. 2. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. 3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. /s/ Rogan Nunn, by power of attorney 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR